Guillain-Barre' Syndrome: A Clinical Summary

Guillain-Barre’ Syndrome is a neurological syndrome that impacts nearly 100,000 patients yearly. This disease is a severe neuropathy resulting in rapidly ascending paralysis. The presentation of Guillain-Barre’ varies depending on the subtype and the region where it is contracted. Antecedent events for Guillain-Barre’s Syndrome are not fully understood, but these are known to include bacterial or viral infections and rarely, immunizations. (Willison et al, 2016). Evidence suggests that molecular mimicry may be a component of antecedent event response, particularly in Campylobacter jejuni infections (Van Doorn, et al 2010). Pathophysiology of the condition differs between the axonal and demyelinating subtypes, as does the length of recovery (Willison et al, 2016). Treatment is guideline-based and is centered around immunotherapy with either immune globulin administration or plasma exchange. (Hughes et al, 2003). Guillain-Barre’ Syndrome presents a unique opportunity for pharmacists to educate patients and providers, lead evidence-based and patient-specific care, and to support patients in the recovery process through excellent symptoms management.